Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial, which randomized 10,061 patients post–myocardial infarction (MI) with hs-CRP ≥2 mg/L to either canakinumab (an IL-1β antibody) or placebo over a 3.7-year follow-up period, provided clinical proof of the role of inflammatio...”
Randomized trial shows improved outcomes for cardiovascular events in patients with atherosclerotic disease, suggesting a new treatment approach.
Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: